Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2017: 3.556

CiteScore 2017: 2.34

SCImago Journal Rank (SJR) 2017: 1.114
Source Normalized Impact per Paper (SNIP) 2017: 1.188

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 44, Issue 9

Issues

Serum cytokine levels and the expression of estrogen and progesterone receptors in breast cancer patients

Malgorzata Fuksiewicz
  • Department of Tumor Markers, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Janina Kaminska
  • Department of Tumor Markers, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Beata Kotowicz
  • Department of Tumor Markers, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maria Kowalska
  • Department of Tumor Markers, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Maryna Rubach
  • Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Tadeusz Pienkowski
  • Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2006-09-08 | DOI: https://doi.org/10.1515/CCLM.2006.192

Abstract

Background: The aim of this study was to assess the correlation between serum concentrations of cytokines and soluble cytokine receptors in breast cancer patients and the expression of estrogen and progesterone receptors in tumor cells.

Methods: The study comprised 158 female breast cancer patients before treatment and 50 healthy individuals as a reference group.

Results: The study revealed significantly higher concentrations of most cytokines in breast cancer patients compared to the reference group. Assessment of the correlation between cytokine concentrations in serum and the expression of estrogen and progesterone receptors in tumor cells showed significantly higher interleukin-8 (IL-8) concentrations in patients lacking progesterone receptors in comparison to patients with these receptors. The concentrations of cytokines and their soluble receptors as a function of the expression of estrogen and progesterone receptors were also analyzed in two age groups. In younger patients, aged 50years and below, no significant differences were found between serum cytokine concentrations and the expression of both estrogen and progesterone receptors. In patients older than 50years, significantly higher IL-8 concentrations were observed in individuals lacking progesterone receptors, whereas IL-1ra was significantly higher in those lacking estrogen receptors.

Conclusions: IL-1ra and IL-8 concentrations in serum, together with a lack of estrogen and progesterone receptors in tumor cells, in breast cancer patients older than 50years could represent additional predictive factors for this disease.

Clin Chem Lab Med 2006;44:1092–7.

Keywords: breast cancer; cytokine; estrogen receptor; progesterone receptor

References

  • 1.

    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57.CrossrefGoogle Scholar

  • 2.

    Bachelot T, Ray-Coquad I, Menetrier-Caux C, Rasthka M, Duc A, Blay J-Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients. Br J Cancer 2003; 88:1721–6.CrossrefGoogle Scholar

  • 3.

    Bozcuk H, Uslu G, Samur M, Yildiz M, Ozben T, Ozdogan M, et al. Tumor necrosis factor-alpha, interleukin-6, and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. Cytokine 2004; 27:58–65.CrossrefGoogle Scholar

  • 4.

    Boumater Steege JC, Beaten CI, Thijssen VL, Satijn SA, Verhoeven IC, Hillen HF, et al. Angiogenic profile of breast carcinoma determines leukocyte infiltration. Clin Cancer Res 2004; 10:7171–8.CrossrefGoogle Scholar

  • 5.

    Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of the breast cancer. Breast Cancer Res 2002; 4:65–9.CrossrefGoogle Scholar

  • 6.

    Reed MJ, Purohit A. Breast cancer and the role of cytokines in regulating estrogen synthesis: an emerging hypothesis. Endocr Rev 1997; 18:701–15.CrossrefGoogle Scholar

  • 7.

    Hanma S, Shimodaira K. The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocrine J 2002; 49:371–7.CrossrefGoogle Scholar

  • 8.

    Pantschenko AG, Pushkar I, Anderson KH, Wang Y, Miller LJ, Kurtzman SH, et al. The interleukin-1 family cytokines and receptors in human breast cancer: implications for tumor progression. Int J Oncol 2003; 23:269–84.Google Scholar

  • 9.

    Nikolic-Vukosavljevic D, Kanjer K, Neskovic-Konstantynovic Z, Vukotic D. Natural history of estrogen receptor-negative, progesterone receptor-positive breast cancer. Int J Biol Markers 2002; 17:196–200.Google Scholar

  • 10.

    Floiras JL, Hacene K, Turpin F, Spyratos F. Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with hight estrogen receptor values? Int J Biol Markers 2000; 15:135–8.Google Scholar

  • 11.

    Pienkowski T. Predictive factors in breast cancer patients. Nowotwory J Oncol 2000; 50:165–70.Google Scholar

  • 12.

    Freud A, Chauveau C, Brouillet JP, Lucas A, Lacroix M, Licznar A, et al. IL-8 expression and its possible relationship with esrtogen-receptor-negative status of breast cancer cells. Oncogene 2003; 22:256–65.CrossrefGoogle Scholar

  • 13.

    Miller LJ, Kurtzman SH, Anderson K, Wang Y, Stankus M, Renna M, et al. Interleukin-1 family expression in human breast cancer: interleukin-1 receptor antagonist. Cancer Invest 2000; 18:293–302.Google Scholar

  • 14.

    Rutkowski P, Kaminska J, Kowalska M, Ruka W, Steffen J. Cytokine serum levels in soft tissue sarcoma patients: correlations with clinico-pathological features and prognosis. Int J Cancer 2002; 100:463–71.CrossrefGoogle Scholar

  • 15.

    Kaminska J, Nowacki MP, Kowalska M, Rysinska A, Chwalinski M, Fuksiewicz M, et al. Clinical significance of serum cytokine measurements in untreated colorectal cancer patients: soluble tumor necrosis factor receptor type I – an independent prognostic factor. Tumor Biol 2005; 26:186–94.CrossrefGoogle Scholar

  • 16.

    Kaminska J, Kowalska M, Nowacki M, Chwalinski M, Rysinska A, Fuksiewicz M. CRP, TNFα, IL-1ra, IL-6, IL-8 and IL-10 in blood serum of colorectal cancer patients. Pathol Oncol Res 2000; 6:38–41.CrossrefGoogle Scholar

  • 17.

    Balsari A, Maier JA, Colnaghi MI, Menad S. Correlation between tumor vascularity, vascular endothelial growth factor production by tumor cells, serum vascular endothelial growth factor levels, and serum angiogenic activity in patients with breast carcinoma. Lab Invest 1999; 79:897–902.Google Scholar

  • 18.

    Coskun U, Gunel N, Toruner FB, Sancak B, Onuk E, Bayram O, et al. Serum leptin, prolactin and vascular endothelial growth factor (VEGF) levels in patients with breast cancer. Neoplasma 2003; 50:41–6.Google Scholar

  • 19.

    Heer K, Kumar H, Read JR, Monson JR, Kerin MJ. Serum vascular endothelial growth factor in breast cancer: its relation with cancer type and estrogen receptor status. Clin Cancer Res 2001; 7:3491–4.Google Scholar

  • 20.

    Wu Y, Saldana L, Chillar R, Vadgama JV. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002; 20:509–16.Google Scholar

  • 21.

    Pichon MF, Moulin G, Pallud C, Pecking A, Floiras JL. Serum bFGF (basic fibroblast growth factor) and CA 15.3 in the monitoring of breast cancer patients. Anticancer Res 2000; 20:1189–94.Google Scholar

  • 22.

    Terasowa P, Kvasnicka J, Umlaufowa A, Homolkowa H, Jirsa M, Tesar V. Soluble TNF and IL-2 receptors in patients with breast cancer. Med Sci Monit 2000; 6:661–7.Google Scholar

  • 23.

    Foekens JA, Peters HA, Grebenchtchikov N, Look MP, Meijer-van Gelder ME, Geurts-Moespot A, et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61:5407–14.Google Scholar

  • 24.

    Fontanini G, Campani D, Roncella M, Cecchetti D, Calvo S, Toniolo Basolo F. Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma. Br J Cancer 1999; 80:579–84.CrossrefGoogle Scholar

  • 25.

    Robinson EK, Sneige N, Grimm EA. Correlation of interleukin 6 with interleukin 1α in human mammary tumors, but not with oestrogen receptor expression. Cytokine 1998; 10:970–6.CrossrefGoogle Scholar

  • 26.

    Pantschenko AG, Pushkar I, Miller LJ, Wang YP, Anderson K, Peled Z, et al. In vitro demonstration of breast cancer tumor cell subpopulations based on interleukin-1/tumor necrosis factor induction of interleukin-8 expression. Oncol Rep 2003; 10:1011–7.Google Scholar

  • 27.

    Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, et al. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 2004; 109:507–14.Google Scholar

  • 28.

    Chelouche-Lev D, Miller CP, Tellez C, Runiz M, Bar-Eli M, Price JE. Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy. Eur J Cancer 2004; 40:2509–18.CrossrefGoogle Scholar

  • 29.

    Zeleniuch-Jacquotte A, Shore RE, Koenig KL, Akhmedkhanov A, Afanasyeva Y, Kato I, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004; 90:153–9.CrossrefGoogle Scholar

  • 30.

    Elkin M, Orgel A, Kleinman HK. An angiogenic switch in breast cancer involves estrogen and soluble vascular endothelial growth factor receptor 1. J Natl Cancer Inst 2004; 96:875–6.CrossrefGoogle Scholar

About the article

Corresponding author: Malgorzata Fuksiewicz, PhD, Department of Tumor Markers, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Roentgena 5, 02-781 Warszawa, Poland Phone/Fax: +48-22-6447607,


Received: 2006-03-16

Accepted: 2006-06-13

Published Online: 2006-09-08

Published in Print: 2006-09-01


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), Volume 44, Issue 9, Pages 1092–1097, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2006.192.

Export Citation

©2006 by Walter de Gruyter Berlin New York.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Kelly Yi Ping Liu, Xian Jun David Lu, Yuqi Sarah Zhu, Nhu Le, Hugh Kim, and Catherine F. Poh
Frontiers in Oncology, 2018, Volume 8
[2]
Murat Yigit, Serkan Değirmencioğlu, Erhan Ugurlu, and Arzu Yaren
Molecular and Clinical Oncology, 2017, Volume 6, Number 5, Page 708
[3]
Anna Majer, Anne A. Blanchard, Sarah Medina, Stephanie A. Booth, and Yvonne Myal
DNA and Cell Biology, 2016, Volume 35, Number 7, Page 328
[4]
Stéphane Perrier, Florence Caldefie-Chézet, and Marie-Paule Vasson
FEBS Letters, 2009, Volume 583, Number 2, Page 259
[5]
Debora Aparecida Pires de Campos Zuccari, Camila Leonel, Rodrigo Castro, Gabriela Bottaro Gelaleti, Bruna Victorasso Jardim, Marina Gobbe Moscheta, Vitor Rafael Regiani, Lívia Carvalho Ferreira, Juliana Ramos Lopes, Dalisio de Santi Neto, and José Luis Esteves
Acta Histochemica, 2012, Volume 114, Number 6, Page 571
[6]
Paul J. Mills, Sonia Ancoli-Israel, Barbara Parker, Loki Natarajan, Suzi Hong, Shamini Jain, Georgia R. Sadler, and Roland von Känel
Brain, Behavior, and Immunity, 2008, Volume 22, Number 1, Page 98
[7]
[8]
Malgorzata Fuksiewicz, Maria Kowalska, Beata Kotowicz, Maryna Rubach, Magdalena Chechlinska, Tadeusz Pienkowski, and Janina Kaminska
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 10
[9]
Beata Kotowicz, Janina Kaminska, Malgorzata Fuksiewicz, Maria Kowalska, Joanna Jonska-Gmyrek, Krzysztof Gawrychowski, Janusz Sobotkowski, Maciej Skrzypczak, Jozef Starzewski, and Mariusz Bidzinski
International Journal of Gynecological Cancer, 2010, Volume 20, Number 4, Page 588
[10]
Charles A. Dinarello
Cancer and Metastasis Reviews, 2010, Volume 29, Number 2, Page 317
[11]
Simi Ali and Gwendal Lazennec
Cancer and Metastasis Reviews, 2007, Volume 26, Number 3-4, Page 401
[13]
B. KOTOWICZ, M. FUKSIEWICZ, M. KOWALSKA, J. JONSKA-GMYREK, M. BIDZINSKI, and J. KAMINSKA
International Journal of Gynecological Cancer, 2008, Volume 18, Number 6, Page 1279
[14]
Magdalena Chechlinska, Maria Kowalska, and Janina Kaminska
Expert Opinion on Medical Diagnostics, 2008, Volume 2, Number 6, Page 691

Comments (0)

Please log in or register to comment.
Log in